[go: up one dir, main page]

WO2012052169A3 - Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid-antagonisten - Google Patents

Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid-antagonisten Download PDF

Info

Publication number
WO2012052169A3
WO2012052169A3 PCT/EP2011/005275 EP2011005275W WO2012052169A3 WO 2012052169 A3 WO2012052169 A3 WO 2012052169A3 EP 2011005275 W EP2011005275 W EP 2011005275W WO 2012052169 A3 WO2012052169 A3 WO 2012052169A3
Authority
WO
WIPO (PCT)
Prior art keywords
opioid
pharmaceutical composition
composition containing
opioid antagonist
particulate pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2011/005275
Other languages
English (en)
French (fr)
Other versions
WO2012052169A2 (de
Inventor
Lars Holger Hermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHOEME GmbH
Original Assignee
PHOEME GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PHOEME GmbH filed Critical PHOEME GmbH
Publication of WO2012052169A2 publication Critical patent/WO2012052169A2/de
Publication of WO2012052169A3 publication Critical patent/WO2012052169A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die Erfindung betrifft eine pharmazeutische Zusammensetzung, die ein Partikel mit dem Opioid und mit dem Opioid-Antagonisten umfasst, wobei die Freisetzung des Opioid-Antagonisten kontinuierlich über einen Zeitraum von 30 Minuten bis zu 8 Stunden nach oraler Verabreichung erfolgt, sowie eine diese enthaltende Darreichungsform zur peroralen Verabreichung.
PCT/EP2011/005275 2010-10-21 2011-10-20 Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid-antagonisten Ceased WO2012052169A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010-236338 2010-10-21
JP2010236338A JP2012087101A (ja) 2010-10-21 2010-10-21 オピオイドおよびオピオイド拮抗薬を含む微粒子医薬組成物

Publications (2)

Publication Number Publication Date
WO2012052169A2 WO2012052169A2 (de) 2012-04-26
WO2012052169A3 true WO2012052169A3 (de) 2012-07-26

Family

ID=44999723

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/005275 Ceased WO2012052169A2 (de) 2010-10-21 2011-10-20 Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid-antagonisten

Country Status (2)

Country Link
JP (1) JP2012087101A (de)
WO (1) WO2012052169A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
US10105360B2 (en) 2013-12-11 2018-10-23 Develco Pharma Schweiz Ag Method and composition for the treatment of opioid induced constipation
EP3079661B1 (de) 2013-12-11 2021-05-05 Algobate AG Naloxon-monopräparat und mehrschichttablette
WO2015089530A1 (de) * 2013-12-20 2015-06-25 G.L. PHARMA GmbH Orale darreichungsform mit verzögerter freisetzung enthaltend morphin und naloxon
IL318587A (en) 2018-07-23 2025-03-01 Trevi Therapeutics Inc Treatment of chronic cough, shortness of breath and wheezing
IL294601A (en) 2020-01-10 2022-09-01 Trevi Therapeutics Inc Methods of administration of nalbuphine
JP2022135015A (ja) * 2021-03-04 2022-09-15 国立大学法人東京工業大学 オピオイド受容体作動剤

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058447A1 (en) * 2000-02-08 2001-08-16 Euro-Celtique, S.A. Controlled-release compositions containing opioid agonist and antagonist
WO2007082935A1 (de) * 2006-01-19 2007-07-26 Phoenux Ag Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen
WO2009085778A1 (en) * 2007-12-17 2009-07-09 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
WO2010121600A2 (de) * 2009-04-22 2010-10-28 Lars Holger Hermann Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid- antagonisten
EP2371356A1 (de) * 2010-03-12 2011-10-05 Lars Holger Hermann Pharmazeutische Mehrfachpartikelformulierung zur Kolonabsorption

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058447A1 (en) * 2000-02-08 2001-08-16 Euro-Celtique, S.A. Controlled-release compositions containing opioid agonist and antagonist
WO2007082935A1 (de) * 2006-01-19 2007-07-26 Phoenux Ag Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen
WO2009085778A1 (en) * 2007-12-17 2009-07-09 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
WO2010121600A2 (de) * 2009-04-22 2010-10-28 Lars Holger Hermann Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid- antagonisten
EP2371356A1 (de) * 2010-03-12 2011-10-05 Lars Holger Hermann Pharmazeutische Mehrfachpartikelformulierung zur Kolonabsorption

Also Published As

Publication number Publication date
JP2012087101A (ja) 2012-05-10
WO2012052169A2 (de) 2012-04-26

Similar Documents

Publication Publication Date Title
WO2012052169A3 (de) Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid-antagonisten
WO2011106416A3 (en) Abuse-resistant formulations
IL233677A (en) Benzysacazole Compounds Aminopyrazolo-Primidine Converted, Pharmaceuticals Containing Them, and Use of Drug Manufacturing Composition
WO2011098582A3 (en) Novel crystalline forms of ivabradine hydrochloride
WO2009114118A3 (en) Oral pharmaceutical compositions of buprenorphine and method of use
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
IL206835A (en) Pharmaceutical compositions containing oil and particulates for oral administration of insulin and methods for their preparation
UA93148C2 (ru) Дозированная форма тароликмуса модифицированного высвобождения
CO6440564A2 (es) Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
EP2447253A4 (de) Dihydropyrimidin-verbindungen und herstellungsverfahren, pharmazeutische zusammensetzungen und verwendungen davon
EA201290734A1 (ru) Рифаксимин в форме порошка, способ его получения и композиции контролируемого высвобождения, содержащие указанный рифаксимин, полезные для достижения длительного эффекта
WO2011157721A3 (en) Ivabradine-containing pharmaceutical composition
IL217500A0 (en) Tetrazole derivatives, their preparartion and pharmaceutical compositions containing them
WO2010121600A3 (de) Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid- antagonisten
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
IL223543A (en) Pharmaceutical preparation containing 1– (4– (4– (4,3-dichloro-2 – fluorophenylamino) –7 – methoxyquinazoline – 6 – Iloxy) piperidine – 1 – il) Prof. 2 – an – 1 – on or a common pharmaceutical salt His and an acidic addition
WO2011104652A3 (en) Veterinary compositions
WO2011141488A3 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2012010669A3 (de) Arzneimittel zur oralen verabreichung umfassend ein gemisch aus silodosin und einem basischen copolymer
IL222092B (en) Compositions and methods for improved retention of a pharmaceutical composition at a local administration site
HK1208222A1 (en) Modified release formulations for oprozomib
WO2012074830A3 (en) Modified release tranexamic acid formulation
WO2012075015A3 (en) Oral metronidazole pharmaceutical compositions
PL2504331T3 (pl) Związek, jego nowe formy, zawierające je kompozycje farmaceutyczne i sposoby otrzymywania oraz zastosowanie

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11784937

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11784937

Country of ref document: EP

Kind code of ref document: A2